Walk on.
Walking better matters. AMPYRA® (dalfampridine) is the first and only medication shown in two clinical trials to improve walking in people with multiple sclerosis (MS). In these clinical studies, people who walked faster reported improvement in their walking-related activities. Not everyone responds to AMPYRA. Individual results may vary. Can be taken in combination with your other MS therapies. Visit Ampyra.com to find out more about a FREE TRIAL.
Talk to your doctor to see if prescription AMPYRA is right for you. In two pivotal trials 35% and 43% of patients taking AMPYRA responded to treatment vs. 8% and 9% of patients taking placebo. Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA. AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. For more information, please see the complete Medication Guide on the next page. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc. AMPYRA is marketed by Acorda Therapeutics, Inc. and is manufactured under license from Alkermes Pharma Ireland Ltd. © 2012 Acorda Therapeutics, Inc. All Rights Reserved. 09/12 AMP1360
PAID ADVERTISEMENT